Skip to main content

Table 4 Glucose metabolism parameters

From: Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C - a randomized trial

 

NGLCD

LFD

 

Baseline

12 months

Mean change

Baseline

12 months

Mean change

FPG (mg/dl)

104.1 ± 27.9

96.9 ± 19.7

−7.2 ± 11.2 [−10.2, - 4.2]

103.7 ± 29.2

96.5 ± 19.1

−7.2 ± 13.1* [−10.8, -3.5]

FPI (μU/ml)

14.2 (11.5-21.8)

9.1 (6.2-16.9)

−7.6 ± 11.5* [−10.7, -4.6]

12.8 (8.7-18.8)

9.15 (6.06-17.08)

−5.2 ± 9.2* [−7.8, -2.6]

HOMA-IR

3.33 (2.3-5.9)

1.99 (1.45-4.04)

−2.4 ± 4.1 * [−3.5, -1.3]

3.06 (1.93-5.11)

2.04 (1.3-4.4)

−1.8 ± 3.9* [−2.9, -0.7]

C Peptide (ng/ml)

2.31 (2.01-2.8)

2.34 (2.08-2.9)

−0.03-0.2 ** [−0.09, -0.03]

2.4 (2.07-2.97)

2.41 (2.1-3.1)

−0.002 ± 0.2*** [−0.004, 0.01]

HbA1c (%)

5.7 ± 0.7

5.6 ± 0.7

−0.11 ± 0.3 * [−0.02, -0.2]

5.6 ± 0.5

5.5 ± 0.5

−0.09 ± 0.2* [−0.06, 0.05]

  1. Values are means ± SD; for variables abnormally distributed we used median ± interquartile ranges (25th and 75th percentiles).
  2. All p >0.05 for difference between groups at baseline and 12 months; *, p < 0.05 for mean change baseline, 12 months; **, p = 0.295; ***, p = 0.925.
  3. NGLCD normoglucidic low-calorie diet, LFD low-fat diet, FPG fasting plasma glucose, FPI fasting plasma insulin, HOMA-IR homeostasis model assessment of insulin resistance, HbA1c glycosylated hemoglobin.